Krishna Institute of Medical Sciences Limited Earnings Summary — Q1 FY2027
KIMS Reports Revenue Growth Amidst Strategic Expansion and ₹15,000 Million QIP Completion
Quarterly Business Intelligence
AI Quarterly Scorecard™
Computed deterministically from the last 10 reported quarters.
Quarterly Business Momentum
- Revenue has increased for 7 consecutive quarters.
- Revenue of ₹1,180 Cr is 35.3% higher year-on-year.
- Revenue has compounded at 31.8% annualised over the last 10 quarters.
- Revenue is at its highest level in 10 quarters.
- Net profit of ₹42 Cr is 47.2% below the same quarter last year.
- Profit growth is trailing revenue growth this quarter.
- Net profit has compounded at -18.4% annualised across the period.
- Operating margin stands at 18.9% in Q1 FY2027.
- Operating margin compressed by 316 bps year-on-year.
- Over the last two years operating margin has contracted by 712 bps.
- PBT margin is 4.8%.
- Expenses grew 40.8% against revenue growth of 35.3%.
- Operating profit of ₹223 Cr is 16.0% higher year-on-year.
- Operating leverage has been under pressure recently.
- 6 of the last 6 measured quarters delivered year-on-year revenue growth.
- Overall quarterly business momentum scores 61/100 (Healthy) on the latest 10 quarters.
- Business momentum has softened and warrants monitoring.
Quarterly Financials
Last 10 Reported Quarters • All figures in ₹ Crore • Margins in %
| Metric | Trend | Latest Q1 FY2027 | Q4 FY2026 | Q3 FY2026 | Q2 FY2026 | Q1 FY2026 | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 | Q4 FY2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | Improving | 1,180 | 1,075 | 998 | 961 | 872 | 797 | 772 | 777 | 688 | 634 |
| Expenses | Improving | 956 | 868 | 799 | 757 | 679 | 599 | 585 | 559 | 509 | 475 |
| Operating Profit | Improving | 223 | 207 | 199 | 204 | 193 | 198 | 187 | 218 | 179 | 159 |
| Operating Margin | Stable | 18.9% | 19.2% | 19.9% | 21.2% | 22.1% | 24.9% | 24.2% | 28.1% | 26.1% | 25.1% |
| Other Income | Volatile | 17 | 1 | 5 | 4 | 7 | 15 | 18 | 5 | 5 | 4 |
| Interest | Strong Uptrend | 83 | 68 | 57 | 45 | 33 | 27 | 26 | 20 | 18 | 16 |
| Depreciation | Improving | 101 | 85 | 79 | 66 | 53 | 53 | 45 | 41 | 39 | 46 |
| Profit Before Tax | Softening | 57 | 55 | 69 | 97 | 114 | 134 | 135 | 162 | 127 | 100 |
| Tax | Stable | 19 | 22 | 17 | 25 | 29 | 28 | 42 | 42 | 32 | 29 |
| Net Profit | Softening | 42 | 43 | 53 | 67 | 79 | 102 | 89 | 107 | 87 | 66 |
| Net Margin | Declining | 3.5% | 4.0% | 5.3% | 7.0% | 9.0% | 12.8% | 11.5% | 13.8% | 12.6% | 10.3% |
Key Takeaways
- Revenue grew by 35.3% YoY to ₹11,795 million, supported by organic and inorganic scaling.
- Successfully completed a Qualified Institutions Placement (QIP) raising ₹15,000 million to fund expansion.
- Consolidated net profit saw a sharp 56% decline YoY, primarily due to increased finance costs and depreciation from new units.
- Finance costs rose significantly from ₹326 million to ₹834 million YoY, reflecting high leverage for hospital projects.
- Expansion continues with the Board approving ₹650 crore in loan limits for subsidiaries and a new O&M agreement with Sarwottam Healthcare.
- The Group entered into a new Hospital Operations and Management Agreement, treated as a business combination under Ind AS 103.
- Promoter group is participating in fund raising through the issuance of 7.7 million convertible warrants worth ₹6,000 million.
Management Guidance
Management is shifting focus toward a national footprint, balancing aggressive capital expenditure for greenfield/brownfield projects with the delivery of affordable quaternary care.
Sentiment Shift
Stable
While revenue growth is robust, the heavy capital expenditure phase is currently weighing on net profitability and return ratios as expected during a scaling cycle.
Outlook
The outlook remains positive for top-line growth as new beds stabilize, although high interest and depreciation will continue to impact near-term bottom-line margins until occupancy rates mature.
From the Annual Report (Key Quotes)
“The balance amounts unutilised have been temporarily invested in mutual fund and kept in monitoring account.”
“The Group operates in one single reportable business segment - 'Medical and Healthcare services'.”
“Approved to advance any loan... not exceeding Rs. 650 Crores over and above the limits available under section 186.”
Official Quarterly Documents
Ask AI about this quarter
This summary is AI-generated from Krishna Institute of Medical Sciences Limited's latest quarterly filing and earnings call. For informational purposes only — not investment advice.
← Back to Krishna Institute of Medical Sciences Limited AI analysis